Is this you?
Request access for Los Angeles Cancer Network with your @lacancernetwork.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Los Angeles Cancer Network
Unclaimed profileSpecialty Network · Los Angeles, CA · ~13+ sites
Intera lens
ICP 4Lift (cardio sample) 0.09Recruit soph 0.29
Quality Scorecard (1–100)
Overall73Recruit52Ops81Sponsor77Ther86
Performance (observed)
Historical trials
323
Completed
96
Terminated/Withdrawn
29
Completion rate
77%
Active now
190
Phase 2
116
Phase 3
182
Realized enrollment
249,753
First study year
1992
Years active
34
Match confidence
high
Enrollment velocity (inf)
7,346
Therapeutic
Areas
Oncology, Hematology
Specialties
Oncology/Blood disorders with expansion to early-phase trials 2026
Breadth (conditions)
1,070
Languages
Y - Korean, Spanish, Farsi, Armenian, others
States
CA
Recruitment (web observed)
Recruitment pages
Yes
Advertises recruitment
Yes
SEO
Y - Blog/news updates
Capability notes
Just beginning early-phase clinical trial recruitment (early 2026 with START Research); currently patient care focused
Relationships
Sponsors
National Cancer Institute (NCI); SWOG Cancer Research Network; NRG Oncology; Alliance for Clinical Trials in Oncology; Pfizer; Novartis Pharmaceuticals
CROs
Medpace, Inc.; PRA Health Sciences; Teva Branded Pharmaceutical Products R&D LLC
Partnerships
OneOncology, START Center for Cancer Research
Owner / parent
OneOncology affiliated (PE-owned)
Funding
OneOncology backed
Expansion
Y - Early-phase trials partnership with START launching 2026
Recent hiring
Y - active careers page
Capacity & people
Investigators
—
Coordinators
—
CEO
Troy Simon
VP Clinical Ops
Unknown
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
323-900-0171 (phone)
Tech & DCT
EHR
Unknown (integrated with OneOncology)
eSource
Yes
Builds tech
Unknown
DCT / decentralized
Y - 25+ clinics across LA/Riverside/Orange counties, community-based model
Recruiting visible
Y
Notes
13+ offices across LA/Orange/Riverside counties. OneOncology affiliated (PE-backed). Just starting early-phase clinical trials in 2026. CMO: Dr. Lasika C. Seneviratne. Limited Intera fit currently due to specialty-only focus (oncology/hematology) and nascent clinical trial program, though PE backing suggests growth potential.
Recommendation features (sample indication)
Ind fit 0.12Liftability 0.09Overall73
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.